FDA approves the Itrevia DX ICD for Arrhythmias-Biotronik

The FDA has approved the Itrevia DX implantable cardioverter defibrillator (ICD), from Biotronik, for patients with complex heart rhythm conditions. The Itrevia DX is a less invasive therapy with an algorithm that can identify successful pain-free therapies for each patient and dynamically re-apply them as needed. The complete Itrevia family - including Itrevia VR-T, Itrevia DR-T, and Itrevia HF-T � were approved together. Also approved is the Inventra DX � the only such ICD system that can deliver ultra-high energy on the first shock; offering better protection to patients that depend on this life-saving therapy. The DX System provides dual-chamber diagnostic capabilities with a single lead, which reduces risks associated with additional hardware for patients while providing valuable clinical information to the physician.